CLSI M43
Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas
This CLSI guideline provides standardized methods for antimicrobial susceptibility testing of human mycoplasmas and ureaplasmas, ensuring accurate and reproducible in vitro measurements of antimicrobial activity. It supports both clinical treatment decisions and the evaluation of new antimicrobials, addressing the growing issue of acquired resistance in these organisms.
The document includes guidelines for performing and ensuring quality control of agar and broth microdilution susceptibility tests, helping laboratories maintain consistency in testing and reporting.
This edition of the document was corrected in March 2015. Read the full correction notice here and learn more about our corrections process here.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceAntimicrobial susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism’s identity. Standardized in vitro antimicrobial susceptibility tests are also needed in order to evaluate new antimicrobials against specific groups of organisms in comparison with existing agents. Acquired resistance to one or more classes of antimicrobial agents has now emerged in the major mycoplasmal and ureaplasmal species that infect humans, hence the need to establish accurate and reproducible methods to measure antimicrobial activities in vitro with these organisms. This document provides guidelines for performance, interpretation, and quality control of in vitro broth microdilution and agar dilution susceptibility tests for several antimicrobial agents suitable for use against Mycoplasma pneumoniae (M. pneumoniae), Mycoplasma hominis (M. hominis), and Ureaplasma species (Ureaplasma spp). Information in this document includes designated reference strains and the expected minimal inhibitory concentration ranges for specific drugs that should be obtained when they are tested.
This document contains standardized protocols for broth microdilution and agar dilution in vitro susceptibility testing for isolates of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma spp. It describes the optimum media formulations for use in broth microdilution and agar dilution assays for each species; provides minimal inhibitory concentration (MIC) quality control (QC) reference ranges for ATCC®a type strains; and offers recommendations for selection of antimicrobials for routine testing and MIC interpretive criteria for a limited number of drugs. This guideline is intended for use by hospital clinical laboratories; reference microbiology laboratories; and government, industry, and academic research organizations that perform diagnostic testing and/or conduct research in mycoplasmal diseases that affect humans.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This document is available in electronic format only.
This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid and because of its value to the laboratory community, it is being retained in CLSI’s library.
This edition of the document has been corrected, read the full correction notice here.
Antimicrobial susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy, if its susceptibility cannot be reliably predicted from knowledge of the organism’s identity. Standardized in vitro antimicrobial susceptibility tests are also needed in order to evaluate new antimicrobials against specific groups of organisms in comparison with existing agents. Acquired resistance to one or more classes of antimicrobial agents has now emerged in the major mycoplasmal and ureaplasmal species that infect humans, hence the need to establish accurate and reproducible methods to measure antimicrobial activities in vitro with these organisms. This document provides guidelines for performance, interpretation, and quality control of in vitro broth microdilution and agar dilution susceptibility tests for several antimicrobial agents suitable for use against Mycoplasma pneumoniae (M. pneumoniae), Mycoplasma hominis (M. hominis), and Ureaplasma species (Ureaplasma spp). Information in this document includes designated reference strains and the expected minimal inhibitory concentration ranges for specific drugs that should be obtained when they are tested.
This document contains standardized protocols for broth microdilution and agar dilution in vitro susceptibility testing for isolates of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma spp. It describes the optimum media formulations for use in broth microdilution and agar dilution assays for each species; provides minimal inhibitory concentration (MIC) quality control (QC) reference ranges for ATCC®a type strains; and offers recommendations for selection of antimicrobials for routine testing and MIC interpretive criteria for a limited number of drugs. This guideline is intended for use by hospital clinical laboratories; reference microbiology laboratories; and government, industry, and academic research organizations that perform diagnostic testing and/or conduct research in mycoplasmal diseases that affect humans.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This document is available in electronic format only.
This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid and because of its value to the laboratory community, it is being retained in CLSI’s library.
This edition of the document has been corrected, read the full correction notice here.